Scott Ryan Goldsmith MD

Hematologic Oncology

Physician

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 314-362-6959

Dr. Goldsmith is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldsmith's full profile Already have an account?

Summary

Dr. Scott Goldsmith is a hematologist and clinical investigator in Duarte (LA), CA and is affiliated with City of Hope Comprehensive Cancer Center. He specializes in the treatment of multiple myeloma and plasma cell dyscrasias, with expertise in cellular therapies, stem cell transplantation, theranostics, and first-in-human clinical trials. He received his medical degree from University of Florida College of Medicine and has been in practice 5 years. He specializes in hematologic oncology. He has more than 30 publications and over 450 citings.

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2013 - 2016
University of Florida College of MedicineClass of 2013

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2021 - 2027
MO State Medical License 2015 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Nov 22
RECRUITING
PHASE1
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2022 May 31
TERMINATED
PHASE1
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) Start of enrollment: 2023 Jul 20
RECRUITING
PHASE1, PHASE2

Publications & Presentations

PubMed

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.
Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid
Transplantation and Cellular Therapy. 2026-06-16
Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases.
Christian H Nenninger, Keith Anderson, Jenaro Espitia-Corredor, Brittany Echevarria, Vertica Agnihotri
Cancer. 2026-05-15
Association of clonal haematopoiesis and diabetes with outcomes after autologous haematopoietic cell transplantation.
Rusha Bhandari, June-Wha Rhee, Sitong Chen, Raju Pillai, Alysia Bosworth
Diabetes, Obesity & Metabolism. 2026-03-01

Abstracts/Posters

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Scott R. Goldsmith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019